Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397117 | 0.98 | DPP4 (0.46) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL29658175 | 0.90 | CAPN1 (0.42) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL29616517 | 0.90 | CAPN1 (0.51) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL29765255 | 0.89 | CAPN1 (0.47) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL30574235 | 0.88 | DPP4 (0.42) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL2184762 | 0.87 | CAPN1 (0.48) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL29408003 | 0.87 | DPP4 (0.45) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL2194423 | 0.87 | CAPN1 (0.48) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL21519838 | 0.87 | CAPN1 (0.48) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL30445980 | 0.86 | CAPN1 (0.41) | DPP7CAPN1CTSBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-02-26 | — | — | US | claimed |
| WO-2025087344-A1 | GLP1-R/GIPR DUAL PEPTIDE AGONISTS AND USE THEREOF | BETA PHARMA, INC. (US) | 2025-05-01 | — | — | WO | claimed |
| EP-4399224-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | Sanofi (FR) | 2024-07-17 | — | — | EP | claimed |
| WO-2023031455-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2023-03-09 | — | — | WO | claimed |
| WO-2022156189-A1 | USE OF POLYPEPTIDE COMPOUND IN PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND INTESTINAL FIBROSIS RELATED THERETO | 深圳市图微安创科技开发有限公司 | 2022-07-28 | — | — | WO | claimed |
| CN-114478744-A | Long-acting GLP-1 antagonist | 成都奥达生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| WO-2025264809-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264785-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025087344-A1 | GLP1-R/GIPR DUAL PEPTIDE AGONISTS AND USE THEREOF | BETA PHARMA, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-118791589-A | Polypeptide synthesis method with long chain side chain | 甘肃瑞德林生物有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4399224-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | Sanofi (FR) | 2024-07-17 | — | — | EP | disclosed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | SHENZHEN TURIER BIOTECH CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| WO-2023031455-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2023-03-09 | — | — | WO | disclosed |
| CN-115768460-A | Long-acting GLP-1/GIP dual agonists | 太阳医药工业有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022156189-A1 | USE OF POLYPEPTIDE COMPOUND IN PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND INTESTINAL FIBROSIS RELATED THERETO | 深圳市图微安创科技开发有限公司 | 2022-07-28 | — | — | WO | disclosed |
| WO-2022156189-A1 | USE OF POLYPEPTIDE COMPOUND IN PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND INTESTINAL FIBROSIS RELATED THERETO | 深圳市图微安创科技开发有限公司 | 2022-07-28 | — | — | WO | disclosed |
| CN-114478744-A | Long-acting GLP-1 antagonist | 成都奥达生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | IAPP, PNLIP, DPP4 | DPP4 3/4885DPP8 13/4885FAP 99/4885 |
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | GIPR, GLP1R, GCG | DPP4 81/4885DPP8 303/4885FAP 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.